Menu
Search
|

Menu

Close
X

BioDelivery Sciences International Inc BDSI.OQ (NASDAQ Stock Exchange Capital Market)

2.10 USD
+0.05 (+2.44%)
As of 12:56 PM EST
chart
Previous Close 2.05
Open 2.05
Volume 15,951
3m Avg Volume 78,964
Today’s High 2.10
Today’s Low 2.00
52 Week High 3.60
52 Week Low 1.58
Shares Outstanding (mil) 55.88
Market Capitalization (mil) 114.56
Forward P/E 21.89
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
49
FY16
16
FY15
48
EPS (USD)
FY17
0.388
FY16
-1.258
FY15
-0.720
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.89
34.59
Price to Sales (TTM)
vs sector
2.15
8.08
Price to Book (MRQ)
vs sector
6.07
5.24
Price to Cash Flow (TTM)
vs sector
10.94
25.98
Total Debt to Equity (MRQ)
vs sector
189.35
15.60
LT Debt to Equity (MRQ)
vs sector
189.35
12.18
Return on Investment (TTM)
vs sector
12.06
13.67
Return on Equity (TTM)
vs sector
80.78
15.40

EXECUTIVE LEADERSHIP

Frank O'Donnell
Executive Chairman of the Board, Since 2012
Salary: --
Bonus: --
Scott Plesha
President, Since 2018
Salary: --
Bonus: --
Ernest De Paolantonio
Chief Financial Officer, Treasurer, Secretary, Since 2015
Salary: $350,000.00
Bonus: $52,500.00
Peter Ginsberg
Vice President - Business Development, Since 2016
Salary: --
Bonus: --
William Stone
Lead Independent Director, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4131 Parklake Ave Ste 225
RALEIGH   NC   27612-2390

Phone: +1919.5829050

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

SPONSORED STORIES